Show items per page
Elements: 7
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group Joly, V.; Moroni, M.; Concia, Ercole; Lazzarin, A.; ... de Cian, W. 2000
add to browser selection
Immunological recovery and antiretroviral therapy in HIV-1 infection Battegay, Manuel; Nuesch, Reto; Hirschel, Bernard; Kaufmann, G. R. 2006
add to browser selection
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens Scherrer, Alexandra U; Böni, Jürg; Yerly Ferrillo, Sabine; Klimkait, Thomas; ... Günthard, Huldrych F 2012
add to browser selection
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals Lubomirov, Rubin; Arab, Mona; Rotger, Margalida; Fayet-Mello, Aurélie; ... Telenti, Amalio 2013
add to browser selection
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study Assoumou, Lambert; Descamps, Diane; Yerly Ferrillo, Sabine; Dos Santos, Georges; ... Masquelier, Bernard 2013
add to browser selection
Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors? Kletenkov, K; Hoffmann, D; Böni, J; Yerly Ferrillo, Sabine; ... Klimkait, T 2017
add to browser selection
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen Fox, Zoe; Phillips, Andrew; Cohen, Cal; Neuhaus, Jacquie; ... Lundgren, Jens 2008